Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 3/20 | 0.33 |
| ▸ | CD14 | P08571 | 3/20 | 0.33 |
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13992486 | 1.00 | TLR4 (0.33) | TLR4CD14LY96HTR1DHTR1B | |
| SCHEMBL13992491 | 0.90 | TLR4 (0.34) | TLR4CD14LY96HTR1DHTR1B | |
| SCHEMBL13992488 | 0.89 | CYP1A2 (0.34) | TLR4CD14LY96HTR1DHTR1B | |
| SCHEMBL10046764 | 0.89 | CYP1A2 (0.34) | TLR4CD14LY96HTR1DHTR1B | |
| SCHEMBL10046754 | 0.84 | HTR1D (0.31) | HTR1DHTR1B | |
| SCHEMBL14680975 | 0.84 | KDM4E (0.43) | TLR4CD14LY96F10PRSS1 | |
| SCHEMBL10046776 | 0.83 | HTR1D (0.33) | HTR1DHTR1BF10PRSS1SMN1; SMN2 | |
| SCHEMBL10046751 | 0.82 | HTR1D (0.34) | TLR4CD14LY96HTR1DHTR1B | |
| SCHEMBL13992485 | 0.82 | HTR1D (0.41) | TLR4CD14LY96HTR1DHTR1B | |
| SCHEMBL13992487 | 0.82 | CYP1A2 (0.32) | HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | CLSPN, BID, CALU | TLR4 3671/4885CD14 2702/4885LY96 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.